suberoyl bis-hydroxamic acid has been researched along with Leucocythaemia in 2 studies
suberoyl bis-hydroxamic acid: antineoplastic, Histone Deacetylase inhibitor
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Salmi-Smail, C | 1 |
| Fabre, A | 1 |
| Dequiedt, F | 1 |
| Restouin, A | 1 |
| Castellano, R | 1 |
| Garbit, S | 1 |
| Roche, P | 1 |
| Morelli, X | 1 |
| Brunel, JM | 1 |
| Collette, Y | 1 |
| Chen, S | 1 |
| Dai, Y | 1 |
| Pei, XY | 1 |
| Grant, S | 1 |
2 other studies available for suberoyl bis-hydroxamic acid and Leucocythaemia
| Article | Year |
|---|---|
Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
Topics: Animals; Antineoplastic Agents; Blood Cell Count; Cell Line, Tumor; Drug Screening Assays, Antitumor | 2010 |
Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-X Protein; Biphenyl Compounds; | 2009 |